New Marketplace
New Risk, New Business Models

Developing Bundled Reimbursement for Cancer Care

Case Study · October 24, 2016

The University of Texas MD Anderson Cancer Center, in conjunction with UnitedHealthcare, implemented prospective bundled payments for patients with head and neck cancer. We successfully developed a method to identify and enroll patients and track performance. The biggest challenges were in claims management and in addressing new technologies.

Key Takeaways

  1. Cancer conditions are good candidates for bundled reimbursement.

  2. Within the provider organization, close collaboration among clinical, financial, and operational teams is essential for success.

  3. The provider/payer relationship must have a foundation of trust and transparency.

  4. Strong project management is necessary to ensure that deadlines are met and barriers addressed in a timely manner.

The Challenge

As health care moves from a fee-for-service system to alternative payment plans, there are few well-tested models. Cancer care, optimally delivered in a multidisciplinary setting, lends itself to a bundled reimbursement approach. However, bundled payments for cancer treatment are in the early stages of development with efforts to-date focused on targeted aspects of care. There is no evidence that bundles control costs or improve outcomes of cancer care — questions we will try to address.

The Execution

MD Anderson partnered with UnitedHealthcare to test the feasibility of bundled reimbursement for multidisciplinary cancer care. We designed a single payment for one year of care for patients with newly diagnosed head and neck cancer. This group was chosen for the pilot due to efficient processes, strong care coordination, participation in prior cost studies, and the insurer’s preference.

First, we modeled the costs of care for a cohort of patients. We found that costs—the biggest being surgery, radiation, hospitalization, intensive care, and imaging — varied based on treatment plan and patient comorbidities, not cancer diagnosis and staging. We proposed four treatment-related payment bundles, with a payment modifier for patients with two or more comorbidities. During weekly meetings with the payer, we negotiated included services for each of the four bundles, patient eligibility criteria, and bundle prices.

We also agreed upon a stop-loss provision, lessening MD Anderson’s financial risk for the few patients (about 1%) incurring significantly higher costs (which could be 4 or 5 times the bundled price) for unanticipated complications.

We worked closely with the clinical team to develop a protocol to verify patient eligibility and define pilot operations. Clinical leaders emphasized the importance of implementing the pilot without impacting patient care.

The Team

The provider and payer teams included clinical, financial, and operational leaders, along with project managers. Lawyers and contracting experts were engaged as needed.

The Metrics

We developed measures to allow us to assess the value of care for enrolled patients — the outcomes and costs. We developed dashboards to track financial and clinical outcomes, including survival and recurrence; complications, such as reoperation and readmission; timeliness of care; time to return to normal activities; and functional status, such as the ability to speak and swallow. We developed systems to collect many of these outcomes via patient-reported outcome tools. Enrollment is under way.

The Timeline

Initial deliberations began in late 2013, with pilot development in 2014. The three-year pilot started in November 2014, with patient enrollment during the first two years.

The Hurdles

The most unexpected hurdle was in claims management. Fee-for-service claims systems are not well configured to test alternative payment models. Bundled payments required manual workarounds by MD Anderson and UnitedHealthcare. Claims and payment processing improved with experience but still lagged behind the automated fee-for-service process. Additionally, proton therapy, a newer technology, was excluded from the bundle (and paid for separately) because it is not a covered service for the pilot population. Barriers to including emerging technologies and innovative therapies are one problem we are working to address in this bundle, and will similarly be a challenge in other bundled reimbursement programs as they evolve.

Next Steps

We will track our performance carefully, comparing the outcomes and costs (including time-driven activity-based costing) of enrolled patients with previously treated patients, to determine whether we are controlling costs and optimizing outcomes. We are also evaluating other cancer conditions that can be paid in this manner.

Where to Start

Within your own organization, identify health conditions that have well-coordinated, integrated care delivery. Engage clinicians in defining which services should be included in a bundled payment. Work with finance leaders to understand your costs of delivering care before establishing a bundle price. Key questions to ask are: Do the clinical, finance, and administrative teams have a good relationship? Can you build the systems to assess your performance in a bundle? How will you measure outcomes and costs, and set performance targets?

Case Study Chart: Developing Bundled Reimbursement for Cancer Care

  Click To Enlarge.

 

The authors thank Ron Walters, MD; Randy Weber, MD; and James Incalcaterra, PhD of MD Anderson Cancer Center and Lee Newcomer, MD, of UnitedHealthcare for their contributions to the development of the pilot.

 

This case study originally appeared in NEJM Catalyst on November 25, 2015.

New Call for Submissions ­to NEJM Catalyst

Connect

A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »

More From New Marketplace

Reframing the Conversation on Drug Pricing

We can’t afford for current trends to continue. There is only one solution.

Health Insurance Price Discounts: 2014 median hospital billed charges and median allowed (negotiated) insurance payments by admission type

The Value of Health Insurance through Price Discounts

How health insurance secures lower prices for health care services, leaving uninsured individuals facing medical debt and difficult choices.

ED Telehealth Express Care Service Patient Room

Revolutionizing the Delivery of Care for ED Patients

How the NYP OnDemand Emergency Department Telehealth Express Care Service reduced stay times and revisit rates in one year.

Targeting Unconscionable Prescription-Drug Prices — Maryland’s Anti–Price-Gouging Law

Why, in the early 21st century, are so many drugs that were cheaply available in the 20th century becoming prohibitively expensive?

The Economics of Indication-Based Drug Pricing

What would indication-based drug pricing accomplish?

Navigating Pharmaceutical Price Increases: A Strategy to Protect Appropriate Use, Reduce Waste, and Identify Therapeutic Alternatives

In the face of major pharmaceutical price increases, Cleveland Clinic developed a strategy to ensure high-quality patient care while maintaining financial stability.

Controlling the Cost of Medicaid

Both political parties should support policies that focus on incentives as a mechanism for improving and sustaining their value.

Resetting the Nation’s Health Care Quality Agenda

Poor measures of care quality have consequences. The National Quality Forum is essential to creating measures that are valid and reliable.

Opportunities for Private-Sector Entrepreneurship in Health Care Transformation

Two veterans of public service say that government can do only so much — which creates attractive business opportunities for entrepreneurs.

Moving Past the EHR Interoperability Blame Game

Why can't EHRs talk to one another? We never created the right incentives, but we pretend that we did.

Connect

A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »

Topics

Reframing the Conversation on Drug Pricing

We can’t afford for current trends to continue. There is only one solution.

Reframing the Conversation on Drug Pricing

We can’t afford for current trends to continue. There is only one solution.

Bundled Payments

33 Articles

Progress and Path Forward on Delivery…

The basic goals of delivery system reform — to promote quality and value in our…

Insights Council

Have a voice. Join other health care leaders effecting change, shaping tomorrow.

Apply Now